

REMARKS

Claims 66-75, 111 and 113-134 were pending. Claims 66-70, 111, 113-122, 124-128, 131, 133 and 134 have been allowed.

Applicants have previously filed an Amendment After Final on April 7, 2006. The Examiner issued an *Advisory Action* on April 28, 2006 which refused entry of Applicants' Amendment After Final on the basis of that the following diseases vascular adhesions, angiofibroma, trachoma, corneal graft neovascularization, hemoangioma scarring, ulcers, malaria, HIV, SIV, and Simian hemorrhagic fever virus were not disclosed on pp. 51-52 of the Specification. All other outstanding rejections were deemed to have been overcome by Applicants' amendments.

Applicants thank the Examiner for the courtesies extended during a telephone interview held on May 8th. During the interview, the Examiner concurred again that all of outstanding rejections have been addressed but for the list of diseases mentioned in the aforementioned paragraph. The Examiner stated that Applicants can simply refile the Amendment with the correct page citation (pp. 85-86) to where these specific diseases are found.

For the sake of completeness, Applicants thus refile this *Supplemental Amendment After Final* and repeat all of the remarks and amendments not previously entered.

Claims 74, 75, 123, 129 and 132 remain rejected under 35 U.S.C. § 112, ¶¶ 1 or 2. Applicants respectfully disagree and traversed these rejections. However, solely to expedite the allowance of the claims, Applicants have amended them accordingly. Specifically, claims 74 and 75 have been amended to include a listing of diseases in the preamble as supported and described on pp. 51-52, 85 (lines 1-22) and 86 (lines 3-5) of the Specification (hemoangioma scarring is disclosed, but was deleted from these claims nevertheless for reasons unrelated to

patentability). Claim 123 has been amended to delete “derived from synthetic or naturally occurring amino acids.” Claim 129 has been amended to add a period. Claim 132 has been amended to delete “derivative”. As such, removal of these rejections is respectfully requested. Applicants note that none of these amendments constitute a surrender or disavowal of any subject matter, but is simply made to expedite allowance of these claims as stated earlier.

Claims 71-73 and 130 are objected to as being dependent on a rejected base claim. However, claims 71-73 are dependent on allowed base claims 66 or 67. Claim 130 is dependent on claim 129, for which a period has been added to overcome the lone remaining rejection. As such, removal of these objections is respectfully requested.

In light of the above amendments and remarks, Applicants respectfully submit that a Notice of Allowance should be issued for all of claims 66-75, 111 and 113-134.

If any outstanding issues remain, the Examiner is invited to telephone Applicants’ undersigned attorneys at her convenience at the number provided below.

No fees are believed due in connection with the filing of this *Amendment After Final*. However, the Director is hereby authorized to charge any required fees and credit any overpayments to Deposit Account No. 50-0540.

Dated: May 8, 2006

Respectfully submitted,

By: /Albert B. Chen/
Albert B. Chen, Reg. No. 41,667
Donald L. Rhoads, Reg. No. 34,705
Kramer Levin Naftalis & Frankel LLP
1177 Avenue of the Americas
New York, New York 10036
(212) 715-9100 (telephone)
(212) 715-8000 (facsimile)